Wacker Biotech, a CDMO, began a strategic collaboration with Boston-based RNAV8 Bio aimed at progressing the development and production of mRNA-based advanced therapies for the biopharma industry.
This new partnership combines Wacker Biotech’s expertise in pDNA/mRNA manufacturing and lipid nanoparticle (LNP) formulation with RNAV8 Bio’s mRNA engineering toolkit, which enhances the noncoding sequences of mRNA strands (UTRs), according to Philippe Cronet, general manager of Wacker Biotech US.
UTRs are crucial for mRNA processing, transport, stability, and translation, and their optimization can significantly improve the efficacy of mRNA-based drug products, added Cronet.
“As the therapeutic potential of mRNA rapidly expands into high-value applications across genetic and common diseases, more predictive control over mRNA function becomes critical. RNAV8’s approach represents a major advance, enabling highly efficient and/or more durable mRNA expression at potentially lower doses,” said Devan Shah, CEO of RNAV8 Bio.
“With its impressive manufacturing capabilities and clear track record in mRNA/LNP GMP production for scaleup, Wacker Biotech is an ideal partner for RNAV8 and its therapeutics collaborators.”
“Drug developers will have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics,” noted Cronet. “Ultimately, this holds the promise of improving drug efficacy and accelerating the development process.”
The post Wacker Biotech Collaborates with RNAV8 Bio on mRNA Therapeutics Development appeared first on GEN - Genetic Engineering and Biotechnology News.
This new partnership combines Wacker Biotech’s expertise in pDNA/mRNA manufacturing and lipid nanoparticle (LNP) formulation with RNAV8 Bio’s mRNA engineering toolkit, which enhances the noncoding sequences of mRNA strands (UTRs), according to Philippe Cronet, general manager of Wacker Biotech US.
UTRs are crucial for mRNA processing, transport, stability, and translation, and their optimization can significantly improve the efficacy of mRNA-based drug products, added Cronet.
“As the therapeutic potential of mRNA rapidly expands into high-value applications across genetic and common diseases, more predictive control over mRNA function becomes critical. RNAV8’s approach represents a major advance, enabling highly efficient and/or more durable mRNA expression at potentially lower doses,” said Devan Shah, CEO of RNAV8 Bio.
“With its impressive manufacturing capabilities and clear track record in mRNA/LNP GMP production for scaleup, Wacker Biotech is an ideal partner for RNAV8 and its therapeutics collaborators.”
“Drug developers will have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics,” noted Cronet. “Ultimately, this holds the promise of improving drug efficacy and accelerating the development process.”
The post Wacker Biotech Collaborates with RNAV8 Bio on mRNA Therapeutics Development appeared first on GEN - Genetic Engineering and Biotechnology News.